Skip to main content

Table 2 The correlations between the pretreatment CRP/ALB ratio and the clinicopathological factors

From: The significance of the C-reactive protein to albumin ratio as a marker for predicting survival and monitoring chemotherapeutic effectiveness in patients with unresectable metastatic colorectal cancer

  Pretreatment CRP/ALB ratio
Low High p value
Gender
 Male 36 21  
 Female 27 15 1.000
Age
 <65 34 19  
 ≥65 29 17 1.000
Location of primary tumor
 Colon 36 21  
 Rectum 27 15 1.000
Detection of unresectable tumor
 Synchronous 34 25  
 Metachronous 29 11 0.143
Histological type
 Well, moderately 51 27  
 Poorly, mucinous 9 3 0.744
Peritoneal dissemination
 Negative 47 33  
 Positive 16 3 0.061
The number of organs affected by metastasis
 One organ 36 18  
 Multiple organs 27 18 0.534
Pretreatment CEA (ng/ml)
 ≤5 9 4  
 >5 53 31 0.765
Molecular targeted therapy
 No 17 12  
 Yes 46 24 0.503
Pretreatment mGPS
 0 63 6  
 1 0 21  
 2 0 9 <0.001
Pretreatment NLR
 <3 41 13  
 ≥3 18 22 0.003
  1. CRP/ALB ratio C-reactive protein to albumin ratio, CEA carcinoembryonic antigen, mGPS modified Glasgow prognostic score, NLR neutrophil to lymphocyte ratio